Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunoglobulin cessation versus oral antibiotic strategies for infection prevention in hematological malignancy with secondary hypogammaglobulinemia
ACTRN12622000359730Phase 3Recruiting
- Sponsor
- Monash University
- Start
- May 2023
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Human normal immunoglobulin G, trimethoprim + sulfamethoxazole, doxycycline, amoxicillin + clavulanate, ciprofloxacin and 1 more in hypogammaglobulinemia and hematopoietic malignancies (3 arms), sponsored by Monash University. Primary endpoint: Event-free survival. Started May 2023; status: recruiting.
02
Drugs
Human normal immunoglobulin Gtrimethoprim + sulfamethoxazoledoxycyclineamoxicillin + clavulanateciprofloxacin
03
Conditions
hypogammaglobulinemiahematopoietic malignancies
Beyond the preview
Go deeper on ACTRN12622000359730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000359730.